Benigno C Valdez

Summary

Affiliation: The University of Texas
Country: USA

Publications

  1. Valdez B, Li Y, Murray D, Champlin R, Andersson B. The synergistic cytotoxicity of clofarabine, fludarabine and busulfan in AML cells involves ATM pathway activation and chromatin remodeling. Biochem Pharmacol. 2011;81:222-32 pubmed publisher
    ..Our results provide a conceptual mechanistic basis for exploring this triple-drug combination in pretransplant conditioning therapy for allo-HSCT. ..
  2. Valdez B, Murray D, Nieto Y, Li Y, Wang G, Champlin R, et al. Synergistic cytotoxicity of the DNA alkylating agent busulfan, nucleoside analogs and suberoylanilide hydroxamic acid in lymphoma cell lines. Leuk Lymphoma. 2012;53:973-81 pubmed publisher
    ..Our results provide a preclinical basis for a clinical trial on using [2 NAs + Bu ± SAHA] combinations as conditioning therapy for patients with chemotherapy-refractory lymphoma undergoing HSCT. ..
  3. Valdez B, Tang X, Li Y, Murray D, Liu Y, Popat U, et al. Epigenetic modification enhances the cytotoxicity of busulfan and4-hydroperoxycyclophosphamide in AML cells. Exp Hematol. 2018;67:49-59.e1 pubmed publisher
    ..Our results therefore provide a rationale for the development of personalized conditioning therapy for patients with P53-mutated and FLT3-ITD-positive AML. ..
  4. Valdez B, Li Y, Murray D, Corn P, Champlin R, Andersson B. 5-Aza-2'-deoxycytidine sensitizes busulfan-resistant myeloid leukemia cells by regulating expression of genes involved in cell cycle checkpoint and apoptosis. Leuk Res. 2010;34:364-72 pubmed publisher
    ..Our results suggest that, depending on tumor p53 status, incorporation of DAC might synergistically improve the cytoreductive efficacy of Bu-based pretransplant regimen in patients with ML. ..
  5. Valdez B, Wang G, Murray D, Nieto Y, Li Y, Shah J, et al. Mechanistic studies on the synergistic cytotoxicity of the nucleoside analogs gemcitabine and clofarabine in multiple myeloma: relevance of p53 and its clinical implications. Exp Hematol. 2013;41:719-30 pubmed publisher
    ..Our results provide a rationale for clinical trials incorporating [Gem+Clo] combinations as part of conditioning therapy for high-risk patients with MM undergoing HSCT. ..
  6. Valdez B, Li Y, Murray D, Ji J, Liu Y, Popat U, et al. Comparison of the cytotoxicity of cladribine and clofarabine when combined with fludarabine and busulfan in AML cells: Enhancement of cytotoxicity with epigenetic modulators. Exp Hematol. 2015;43:448-61.e2 pubmed publisher
    ..Our results provide a basis for supplanting Clo with Clad and for including epigenetic modifiers in the pre-hematopoietic stem cell transplantation conditioning regimen for myeloid leukemia patients. ..
  7. Ji J, Valdez B, Li Y, Liu Y, Teo E, Nieto Y, et al. Cladribine, gemcitabine, busulfan, and SAHA combination as a potential pretransplant conditioning regimen for lymphomas: A preclinical study. Exp Hematol. 2016;44:458-65 pubmed publisher
  8. Valdez B, Brammer J, Li Y, Murray D, Teo E, Liu Y, et al. Romidepsin enhances the cytotoxicity of fludarabine, clofarabine and busulfan combination in malignant T-cells. Leuk Res. 2016;47:100-8 pubmed publisher
    ..Our results provide the basis for a clinical trial to evaluate [Flu+Clo+Bu+Rom] as part of conditioning regimen for refractory T-cell malignancy patients undergoing stem cell transplantation. ..
  9. Valdez B, Nieto Y, Murray D, Li Y, Wang G, Champlin R, et al. Epigenetic modifiers enhance the synergistic cytotoxicity of combined nucleoside analog-DNA alkylating agents in lymphoma cell lines. Exp Hematol. 2012;40:800-10 pubmed publisher
    ..This study provides a rationale for an ongoing clinical trial in our institution using (BMG+suberoylanilide hydroxamic acid) as pre-hematopoietic stem cell transplantation conditioning for lymphoma...

More Information

Publications10

  1. Valdez B, Hassan M, Andersson B. Development of an assay for cellular efflux of pharmaceutically active agents and its relevance to understanding drug interactions. Exp Hematol. 2017;52:65-71 pubmed publisher